The poor prognosis of patients with advanced bone and soft-tissue sarcoma has not changed in the past several decades, highlighting the necessity for new therapeutic approaches. Immunotherapies, including oncolytic viral (OV) therapy, have shown great promise in a number of clinical trials for a variety of tumor types. However, the effective application of OV in treating sarcoma still remains to be demonstrated. Although few pre-clinical studies using distinct OVs have been performed and demonstrated therapeutic benefit in sarcoma models, a side-by-side comparison of clinically relevant OV platforms has not been performed. Four clinically relevant OV platforms (Reovirus, Vaccinia virus, Herpes-simplex virus and Rhabdovirus) were screened for their ability to infect and kill human and canine sarcoma cell lines in vitro, and human sarcoma specimens ex vivo. In vivo treatment efficacy was tested in a murine model. The rhabdovirus MG1 demonstrated the highest potency in vitro. Ex vivo, MG1 productively infected more than 80% of human sarcoma tissues tested, and treatment in vivo led to a significant increase in long-lasting cures in sarcoma-bearing mice. Importantly, MG1 treatment induced the generation of memory immune response that provided protection against a subsequent tumor challenge. This study opens the door for the use of MG1-based oncolytic immunotherapy strategies as treatment for sarcoma or as a component of a combined therapy. Sarcomas are a rare and heterogeneous group of aggressive malignant solid tumors that, unlike carcinomas originating from epithelium, arise from a variety of mesenchymal tissues, such as muscle, connective tissue and bone. Sarcomas require a multimodal therapeutic approach that consists of multiagent chemotherapy, surgical resection and radiation. According to the National Cancer Institute, the overall 5-year survival rate for sarcoma patients is 50%, which drops to <20% for cases involving distant metastatic spread. As such, new treatment options for recurrent/metastatic sarcoma are direly needed.
Sarcomas are a rare and heterogeneous group of aggressive malignant solid tumors that, unlike carcinomas originating from epithelium, arise from a variety of mesenchymal tissues, such as muscle, connective tissue and bone. Sarcomas require a multimodal therapeutic approach that consists of multiagent chemotherapy, surgical resection and radiation. According to the National Cancer Institute, the overall 5-year survival rate for sarcoma patients is 50%, which drops to <20% for cases involving distant metastatic spread. As such, new treatment options for recurrent/metastatic sarcoma are direly needed.
Immunotherapy could provide an alternative to chemotherapy yet there has been little focus on sarcoma in this field. This is likely due to sarcoma's heterogeneous nature and the relatively smaller number of patients it affects compared to carcinomas. However, immune checkpoint inhibitors, which have revolutionized the immunotherapy field and that have been very successful to date in melanoma (e.g., anti-CTLA4, anti-PD-1), have so far failed as monotherapies for sarcoma. 1 Oncolytic viruses (OVs) constitute another form of an immunotherapy platform that has showed promising results in a broad range of cancers. OVs are engineered to take advantage of several hallmarks of cancer in order to preferentially replicate in tumor cells. Cancer-selective infection by OVs leads to cancer cell lysis and the parallel production of inflammatory cytokines, leading to innate and adaptive immune responses against both virus and tumor. 2 OV treatment can lead to profound anti-tumor immune responses and cures in at least a subset of patients. 3, 4 Amgen's oncolytic HSV-1 was recently the first OV to be approved by the US food and drug administration (FDA) for treatment of melanoma. 5 Following in these footsteps, a variety of OVs are being tested clinically, including and not limited to vaccinia virus (VV), reovirus, vesicular stomatitis virus (VSV) and the closely related maraba MG1 (Marabex TM ). Contrasting sharply with carcinoma, only few pre-clinical studies have evaluated the efficacy of OV therapies in sarcoma models. Nonetheless, several OVs have been reported to effectively infect and kill human sarcoma cells in vitro.
sarcoma progression [6] [7] [8] 10, 11 and a high frequency of complete response was observed in at least some studies.
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While these studies suggest that OVs may be a promising therapeutic avenue for sarcoma, there have been to date no head-tohead comparisons between different clinically relevant OVs in the context of sarcoma. This limits our ability to evaluate which OV(s) may be the most promising to move forward in sarcoma clinical trials. Also, most studies have exclusively employed xenograft models, 6,7 which do not recapitulate the important role of the immune system, for better or for worse, 10 in the response to OV therapy. In this study, we set out to evaluate the potential of a subset of promising OVs in parallel in the context of sarcoma cell lines and human sarcoma explants obtained following surgery.
The most promising OV based on those results was subsequently tested in an immunocompetent animal sarcoma model.
Material and Methods

Cells
Human bone osteosarcoma (143B), human Ewing's sarcoma (RD-ES), canine osteosarcoma (D17), human synovial sarcoma (SW982), mouse sarcoma (S180) and mouse breast cancer (4T1) cells were from ATCC, Manassas, VA.
Viruses
The 
Sarcoma animal model
Virus replication in vivo: S180 (1 3 10 6 ) tumors were established subcutaneously in 6-week-old female Balb/C mice (N 5 10 per group). Palpable tumors formed within 11 days after seeding. MG1 was administered intra-tumoraly or intravenously (1 3 10 8 pfu/mouse).
Efficacy studies: S180 tumors were treated with three doses of MG1 given intra-tumorally (1 3 10 8 pfu/mouse) at days 8, 10 and 13, post-tumor implantation. Tumors were measured every 2-4 days using an electronic caliper. Tumor volume was calculated as (L 1 ) 2 3 (L 2 )/2.
Immunohistochemistry
Formalin-fixed S180 tumors harvested from mice treated with MG1 or with PBS were paraffin embedded and cut into 5 mm sections. Sections were deparafinized with 3% H 2 O 2 in tris buffered saline (TBS) for 10 min, rinsed in TBS for 5 min, blocked with universal blocking agent Background Sniper (Biocare Medical; Brampton, ON, Canada) for 20 min, incubated with primary antibody rabbit anti-VSV serum (12-24 hr 48C) in 5% normal goat serum (NGS) blocking reagent (Cell signaling Technology, Danvers, MA). Secondary antibody goat anti-rabbit IgG (Jackson ImmunoResearch Laboratory, Pike West Grove, PA) was used in 5% NGS for 1 hr and developed for 5 min with 3,3-diaminobenzidine (DAB) chromatogen kit (Biocare Medical, Concord, CA). Uninfected S180 tumor tissue was used as a negative control. Slides were counterstained in hematoxylin for 1 min and mounted on cover slips with permount.
Ex vivo infection
Primary cancer and normal tissue specimens were obtained from consenting patients who underwent tumor resection. Sample processing has been described previously. 17 
Fluorescence microscopy
To detect GFP production from recombinant MG1, human samples of tumor or normal tissue infected ex vivo as described above were observed under Axiovert S100 Fluorescence microscope 24hpi (Carl Zeiss Ltd, Toronto, ON).
Animal care
All animals were handled in strict accordance with good animal practice as defined by the relevant national and local animal
What's new?
The prognosis for advanced sarcoma remains poor, and new approaches to treatment are urgently needed. In this study of various oncolytic viral (OV) therapies, the authors found that a rhabdovirus called MG1 produced the most promising response in mice. In addition, MG1 treatment induced the generation of a memory immune response that provided protection against a subsequent tumor challenge. These results suggest that MG1-based oncolytic immunotherapy may offer a promising treatment strategy for sarcoma, either alone or as a component of a combined therapy.
welfare bodies, and approved by appropriate committee in collaboration with the Office of Animal Ethics and Compliance (University of Ottawa, Animal Care Committee, OGHRI-58 protocol, Dr. Jean-Simon Diallo).
Consent for use of human specimens
The institutional review board of Ottawa Hospital Research Institute approved all studies involving human tissue specimens (OHREB#2003109-01H). Declaration of Helsinki protocols were followed and patients gave their written, informed consent.
Statistical analysis
Students t test was used to assess the statistical significance of differences observed between treatment groups in vitro and in vivo. Survival studies: Gehan-Breslow-Wilcoxon test was used to determine the statistical significance of the therapeutic effect of MG-1 compared to control. P-values <0.05 were considered significant.
Results
Oncolytic rhabdoviruses are effective against sarcoma cell lines in vitro
As a first assessment of the potential of OV candidates as treatment for sarcoma, we compared head to head five promising OV platforms for their capacity to kill sarcoma cells in vitro.
Herpes Simplex Virus-1 (HSVN212-eGFP; HSV), Reovirus (Reolysin; Reo), VV (VVdd-eGFP; VVdd) and two Rhabdoviruses, Vesicular Stomatitis Virus (VSVD51-GFP; VSVD51) and Maraba virus (MG1-eGFP; MG1), were tested in four different sarcoma cell lines. Human osteosarcoma (143B), canine osteosarcoma (D17), human Ewing's sarcoma (RD-ES) and human synovial sarcoma (SW982) were infected in vitro with different multiplicity of infection (MOI) of each OV. EC50 (effective concentration 50%) values were then determined at 48 hr postinfection (Fig. 1) . While cell lines showed variable sensitivities to OVs, both rhabdoviruses (MG1 and VSVD51) consistently demonstrated a high potency in their ability to kill sarcoma cells. However, MG1 was slightly more effective than VSVD51 for the majority of cell lines tested (Figs. 1a and 1c-1e), as it required a lower MOI to induce >50% cell death. These findings are consistent with a previous report evaluating rhabdoviruses in a panel of adenocarcinoma cell lines. 14 Although it required a higher MOI to induce sufficient cell death than for MG1, VVdd also demonstrated potent killing ability in several sarcoma cell lines. Reovirus and HSV were only effective in RDES Ewing's sarcoma cells. Indeed, this cell line was highly sensitive to all OVs tested. In contrast, SW982 synovial sarcoma cells were the most resistant cell line to OV infection (Fig.  1d ). D17 and 143B osteosarcoma cell lines exhibited an intermediate sensitivity to OVs (Fig. 1e ), but were mostly refractory to both HSV and Reo. These data suggest that rhabdovirusbased OV platforms are more efficient at inducing virusmediated cell death in vitro in a diverse set of sarcoma cell lines.
Human sarcoma specimens are susceptible to MG1 infection ex vivo
We next tested the ability of two of the most effective OV platforms in vitro, MG1 and VVdd, to productively infect human sarcoma specimens ex vivo. For many OV platforms, productive infection as defined by an infection that leads to release of infectious viral progeny is considered important for the efficacy of OVs in vivo, particularly in the context of OVs encoding transgenes whose expression is directly linked to viral replication (e.g., rhabdoviruses). [18] [19] [20] Therefore, measurement of virus replication ex vivo is a great alternative to assessing virus-mediated cancer cell killing since virus-induced cytotoxicity is difficult to accurately measure in live patient's specimens. 18 Human specimens freshly collected following surgery were processed and analyzed according to our previously published method. 21 Tissues that presented low viability assessed using alamar blue prior to processing were excluded from the analysis. A total of 21 specimens representing distinct sarcoma subtypes were subsequently cored and infected ex vivo with MG1 (Supporting Information Fig. 2 ) and 29 for VVdd (Supporting Information Fig. 3 ). Figure 2a shows the distribution of the sarcoma subtypes for MG-1-infected cores: osteosarcoma (OST, 29%), undifferentiated pleomorphic sarcoma (UPS, 24%), chondrosarcoma (CDS, 14%), leiomyosarcoma (LMS, 10%), rhabdomyosarcoma (RMS, 4%) and other types of sarcoma (O, 19%). Viral production was determined by plaque assay and expressed as a fold-change over input. We detected MG1 virus in 95% of the specimens tested (20 of the 21). Importantly, 86% of the samples (18 of the 21) showed productive viral replication ( Fig. 2b ; virus levels exceeding that of virus input). In contrast, productive infection with VVdd was much less frequent and therefore eight additional specimens (3 UPS, 4 O and 1 RMS) were infected only with VVdd. In total, only 58% of specimens infected with VVdd (17 of the 29) had detectable VVdd by plaque assay. Furthermore, only 24% (7 out of 29) showed evidence of productive infection that, on average, was several orders of magnitude lower than that observed for MG1 (Supporting Information Fig. 1 ). As MG1 expresses eGFP, eGFP expression was used as an additional measurement of tumor-specific OV infection in MG1-infected sarcoma or normal tissue specimens, originating from patients with diverse sarcoma etiologies. Regardless of sarcoma type, eGFP expressed from the MG1 virus was abundantly detected by fluorescent microscopy in sarcoma tissue, which corroborates and confirms our findings that MG1 productively infects sarcoma specimens (Fig. 2c) . As expected, we did not detect GFP expression in normal tissues, indicating virus replication is restricted to cancer cells. Collectively, these results suggest that MG1 is more effective than VVdd in its capacity to productively replicate in human sarcoma tissues ex vivo.
MG1 is an efficient therapeutic treatment in vivo
Our in vitro and ex vivo data led us to select MG1 for further in vivo evaluation as treatment for sarcoma. Given the potential contribution of the immune response in eliciting the anti-tumor effects of OV therapy, we tested MG1 on murine S180 metastatic sarcoma cells implanted subcutaneously in immune-competent Balb/C mice. We first tested whether MG1 could kill S180 cells in vitro (Supporting Information Fig. 4 ). Indeed we found that similarly to most human and canine cell lines, S180 cells were highly susceptible to MG1 killing (EC50 <0.0001). We subsequently tested whether MG1 could productively infect S180 tumors in vivo after intra-tumoral (i.t.) or intra-venous (i.v.) injection, as well as ex vivo in tumors collected from tumor-bearing mice (Fig. 3) . Similar to human specimens, ex vivo infection of tumor cores induced productive viral infection as depicted by plaque assay (Fig. 3a) and eGFP expression (Fig. 3b) . We observed that i.v. injection of MG1 did not lead to a productive viral replication in the tumor (Fig. 3a) . However, we were able to detect virus infection after i.t. injection by both plaque assay of homogenized tumor and immunohistochemistry (Figs. 3a and 3c) . Therefore, i.t. delivery of the virus was chosen to assess the effectiveness of MG1 to treat Balb/C mice bearing S180 subcutaneous sarcoma tumors. A schematic representation of the treatment regimen is shown in Figure 3d . Even though spontaneous remissions were observed in 40% of tumor-bearing mice injected with PBS (6/ 15), MG1 treatment slowed tumor progression (Fig. 3e) and significantly increased the number of cured mice (80%, 11/ 15; p values 5 0.0276; Fig. 1f ). To further investigate whether cured mice could reject new S180 tumors following S180 rechallenge, S180 tumor cells were re-implanted (Day 90) on the opposite flank of cured mice from both PBS and MG1 treated groups (PBS 5 6; MG1 5 11; Fig. 3d ). While 100% of spontaneously cured mice from the PBS group developed tumors a week later, only 27% (3/11) of MG1-cured mice rechallenged with S180 cells developed tumors (Fig. 3g ) and these were smaller in size as compared to those from the PBS group (Fig. 3h) . However, similar percentage tumor take rate was observed in PBS and MG1-cured mice after challenge with syngeneic 4T1 breast cancer cells compared to na€ ıve PBS group (Fig. 3i) . Altogether, these results suggest that MG1 delivered i.t. effectively replicates in S180 murine sarcoma tumors implanted in immunocompetent hosts, leading to eradication of 80% of tumors and protection from S180-specific re-challenge in all cured mice.
Discussion
Sarcoma currently requires a multimodal treatment approach, relying primarily upon surgical resection, with adjuvant chemotherapy and/or radiation therapy. 22 This aggressive approach is quite taxing for patients. Our study suggests that the oncolytic rhabdovirus MG1 has potential for the treatment of sarcoma. Among several other clinically relevant candidate OVs, MG1 was the most potent OV based on in vitro cell killing across a panel of four sarcoma cell lines. Close behind MG1 was VSVD51, another oncolytic rhabdovirus, followed by the vaccinia-based OV candidate, VVdd. However, from a heterogeneous panel of human sarcoma tissue processed ex vivo, we observed that MG1 outperformed VVdd in the ability to infect and replicate in tumor tissue. Overall, we found that the difference between Vaccinia and MG-1 observed in in vitro cytotoxicity assays was in line with the tissue explant viral growth data, wherein MG-1 grew more effectively than Vaccinia. However, we acknowledge there may be a number of normal cells (e.g., immune cells, endothelial cells and cancer associated fibroblasts) that could further influence the capacity of viruses to infect tissue explants.
Lastly, using the immunocompetent murine subcutaneous S180 sarcoma model, we showed that MG1 treatment led to significantly more durable cures compared to control. Upon subsequent re-challenge with the same tumor cells, mice previously treated with MG1 were more readily protected from tumor re-growth. One caveat is that S180 tumors had a high frequency of spontaneous regression, which has been reported by other groups. 23 Also given OV treatment for sarcomas would likely be assessed in the context of tumor resection, it will be interesting to pursue subsequent studies characterizing the effect of MG1 administered perioperatively following tumor resection or amputation in animal models. However, there is a general paucity in murine sarcoma models, which makes these studies challenging. Given, we have shown that MG1 is effective in D17 canine sarcoma cells, a canine study would be of particular interest given the naturally high prevalence of osteosarcoma in dogs 23 and the similarity of clinical of disease progression and treatment in the veterinary setting.
Finally, while it seems less effective than MG1 and VSVD51, VVdd was also capable of killing sarcoma cell lines in vitro, and was able to infect a small proportion of ex vivo human sarcoma samples. However, it is unclear whether the same level of infection with VVdd is required to elicit an anti-tumor effect as compared to MG1. Our group has shown in clinical trials that intravenous injection of the VV JX-594 (3.10 e7 pfu kg 21 ) led to replication of the virus in one patient with leiomyosarcoma, resulting in >16 weeks disease control by RECIST criteria. 4 Hence, this platform may merit more investigation for sarcoma treatment. Overall, our study open doors to use viral immunotherapeutic-based platform to treat sarcoma. Notably, Maraba virus MG1 is clearly a promising candidate, which warrants further evaluation either alone or in a prime-boost strategy.
